These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9272900)

  • 21. Primary pulmonary hypertension associated with the use of fenfluramine derivatives.
    Simonneau G; Fartoukh M; Sitbon O; Humbert M; Jagot JL; Hervé P
    Chest; 1998 Sep; 114(3 Suppl):195S-199S. PubMed ID: 9741568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selections from current literature: pharmacological treatment of obesity.
    Connolly J; Verni C; Trilling J; Kelso E; Shiesha S
    Fam Pract; 1998 Feb; 15(1):88-93. PubMed ID: 9527304
    [No Abstract]   [Full Text] [Related]  

  • 23. Fluoxetine is a safer alternative to fenfluramine in the medical treatment of obesity.
    Anchors M
    Arch Intern Med; 1997 Jun; 157(11):1270. PubMed ID: 9183245
    [No Abstract]   [Full Text] [Related]  

  • 24. Aminorex, dexfenfluramine, and primary pulmonary hypertension.
    Kramer MS; Lane DA
    J Clin Epidemiol; 1998 Apr; 51(4):361-4. PubMed ID: 9539893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Anorectics and pulmonary hypertension].
    Bíbová J; Hampl V
    Cas Lek Cesk; 2000 Feb; 139(3):67-70. PubMed ID: 10838744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fenfluramine potentiates canine pulmonary vasoreactivity to endothelin-1.
    Barman SA; Isales CM
    Pulm Pharmacol Ther; 1998; 11(2-3):183-7. PubMed ID: 9918753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High altitude may be synergistic with pulmonary hazards of appetite control medications fenfluramine and dexfenfluramine.
    Davis WM; Waters IW
    Med Hypotheses; 1997 Dec; 49(6):509-12. PubMed ID: 9466375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fen-phen manufacturers, not physicians, are liable.
    Allen S; Henderson J
    Tex Med; 2000 May; 96(5):62-4. PubMed ID: 10843016
    [No Abstract]   [Full Text] [Related]  

  • 29. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography.
    Mast ST; Jollis JG; Ryan T; Anstrom KJ; Crary JL
    Ann Intern Med; 2001 Feb; 134(4):261-6. PubMed ID: 11182835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serotonin 5-HT(2B) receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension.
    Blanpain C; Le Poul E; Parma J; Knoop C; Detheux M; Parmentier M; Vassart G; Abramowicz MJ
    Cardiovasc Res; 2003 Dec; 60(3):518-28. PubMed ID: 14659797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension.
    Rothman RB; Ayestas MA; Dersch CM; Baumann MH
    Circulation; 1999 Aug; 100(8):869-75. PubMed ID: 10458725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Appetite suppressants and heart valve disorders].
    Adams C; Cohen A
    Arch Mal Coeur Vaiss; 1999 Sep; 92(9):1213-9. PubMed ID: 10533670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium.
    Delcroix M; Kurz X; Walckiers D; Demedts M; Naeije R
    Eur Respir J; 1998 Aug; 12(2):271-6. PubMed ID: 9727773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension.
    Archer SL; Djaballah K; Humbert M; Weir KE; Fartoukh M; Dall'ava-Santucci J; Mercier JC; Simonneau G; Dinh-Xuan AT
    Am J Respir Crit Care Med; 1998 Oct; 158(4):1061-7. PubMed ID: 9769261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A role for potassium channels in smooth muscle cells and platelets in the etiology of primary pulmonary hypertension.
    Weir EK; Reeve HL; Johnson G; Michelakis ED; Nelson DP; Archer SL
    Chest; 1998 Sep; 114(3 Suppl):200S-204S. PubMed ID: 9741569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serotonin transporters, serotonin release, and the mechanism of fenfluramine neurotoxicity.
    Baumann MH; Ayestas MA; Dersch CM; Partilla JS; Rothman RB
    Ann N Y Acad Sci; 2000 Sep; 914():172-86. PubMed ID: 11085319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anorexigen-related cardiopulmonary toxicity.
    Gross SB; Lepor NE
    Rev Cardiovasc Med; 2000; 1(2):80-9, 102. PubMed ID: 12457145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Too late, again?
    Jones NL
    Can Respir J; 2001; 8(3):127-8. PubMed ID: 11420587
    [No Abstract]   [Full Text] [Related]  

  • 39. Fenfluramine-like cardiovascular side-effects of benfluorex.
    Boutet K; Frachon I; Jobic Y; Gut-Gobert C; Leroyer C; Carlhant-Kowalski D; Sitbon O; Simonneau G; Humbert M
    Eur Respir J; 2009 Mar; 33(3):684-8. PubMed ID: 19251806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dexfenfluramine and serotonin neurotoxicity: further preclinical evidence that clinical caution is indicated.
    McCann U; Hatzidimitriou G; Ridenour A; Fischer C; Yuan J; Katz J; Ricaurte G
    J Pharmacol Exp Ther; 1994 May; 269(2):792-8. PubMed ID: 7514223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.